UCB Group's bimekizumab may be well behind the competition in the crowded fields of psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) but to paraphrase Bob Dylan, the slow one now may later be fast if the Belgian drug maker's product candidate continues to hit the high endpoints the company has been setting in clinical studies.
The latest set of strong data on the monoclonal antibody which inhibits both interleukin-17A and IL-17F were presented at the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
